***You are invited to attend:***





***Bipolar Disorder- An Overview of Practical Issues***

**Speaker:**

***Dr. Michael Rosenbluth*** *MD FRCPC*

*Chief, Department of Psychiatry, Michael Garron Hospital/ Toronto East Health Network, Associate Professor University of Toronto*

|  |  |
| --- | --- |
| **Wednesday: July 14th3h, 2021 7:00 pm EST**  **Zoom Virtual Presentation**  [https://sdpa.zoom.us/j/93443217504?pwd=V0dsdXNRejB2VHA3TDRyVllieE0ydz09](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fsdpa.zoom.us%2Fj%2F93443217504%3Fpwd%3DV0dsdXNRejB2VHA3TDRyVllieE0ydz09&data=04%7C01%7CTamara.Dobbin%40sunovion.com%7C6250f9d09e4e418b352a08d93b4538a6%7Ce08b136405d24b7e877d5cf19ce86baa%7C1%7C0%7C637605990776439897%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=mLdNcV6neNf6fnfSxpRFdbi1%2BZ1qcWyxtStIq2QK4%2Bo%3D&reserved=0) | |
| **Learning Objectives:** | 1. Consider the issue of treatment refractory depression. Is it sometimes Bipolar? 2. Improving the treatment of Bipolar Depression-Meds/Counselling/Screening. 3. Latuda- Where does it fit in? |
| **Sponsored by:**  Tamara Dobbin Sunovion Pharmaceuticals Representative  Cell: 647-400-9580 or [tamara.dobbin@sunovion.com](mailto:tamara.dobbin@sunovion.com) | |

